Buy, hold, sell: Sonic Healthcare, AMP, CBA shares
The ASX 200 fell 1.6% to 9,115.2. Sonic Healthcare (SHL) edged down 0.1% to $22.37; Bell Potter reiterated a buy, citing low EV/EBITDA and FY27e PE ~16x. AMP (AMP) fell 0.9% to $2.33 after 1H FY26 underlying NPAT +33% to $174m, AUM $167.6b, plus $150m buyback and 3c interim dividend. CBA (CBA) fell 4.1% to $167.17; cash NPAT +7% to $11b, NIM 2.05%, dividend $2.70, with a sell call from Dolphin Partners.
How this was made
The 30-second read
Why it matters
The only concrete, decision-relevant disclosures in the text are AMP’s 1H FY26 underlying NPAT increase plus the $150m buyback and 3c interim dividend. SHL and CBA are driven mainly by valuation framing and analyst ratings rather than new company-specific datapoints in this article.
Market read
Traders get a quick read on how analysts are positioning around valuation and recent results, with AMP’s capital return and profit growth being the most concrete catalyst in the text.
What to watch
The article does not quantify consensus expectations or guidance beyond the cited metrics, so the magnitude of any surprise versus market expectations is unclear.
Background
A multi-stock “buy, hold, sell” roundup for ASX 200 names, citing analyst views and selected recent financial metrics.
Ticker impact
AMP is discussed after reporting 1H FY26 underlying NPAT up 33% to $174m, with a $150m on-market buyback and a 3c interim dividend.
Moderate positive bias for AMP as traders weigh buyback and dividend support against the hold-rating framing.
The article includes specific, attributable financial results and capital return details, which can drive near-term repricing.
Market effects
Healthcare and financials are both referenced, but the piece is primarily stock-specific ratings rather than a sector catalyst.
ASX 200 is noted down 1.6% last Friday, but no new macro driver is provided.
Limited, as the article is focused on Australian company results and local analyst commentary.
Counterpoint
AMP’s hold rating could be overly cautious if the buyback and AUM growth translate into sustained earnings momentum; CBA’s NPAT growth may offset NIM pressure more than the sell thesis implies.
Key entities
- companySonic Healthcare Ltd
ASX 200 healthcare provider discussed with a buy rating and valuation context near decade lows on EV/EBITDA.
- companyAMP Ltd
Financial services firm discussed after 1H FY26 underlying NPAT rose 33% to $174m, alongside a $150m on-market buyback and 3c interim dividend.
- companyCommonwealth Bank of Australia
Major Australian bank discussed with a sell rating after cash NPAT rose 7% to $11b but NIM fell to 2.05% and growth is slowing.
